From Discovery to Implementation: Bringing Proteomics to the Clinic

From Discovery to Implementation: Bringing Proteomics to the Clinic | Authorea try { document.documentElement.classList.add('js'); } catch (e) { } var _gaq = _gaq || []; _gaq.push(['_setAccount', 'G-8VDV14Y67G']); _gaq.push(['_trackPageview']); (function() { var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true; ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js'; var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s); })(); Skip to main content Preprints Collections Wiley Open Research IET Open Research Ecological Society of Japan All Collections About About Authorea FAQs Contact Us Quick Search anywhere Search for preprint articles, keywords, etc. Search Search ADVANCED SEARCH SCROLL PROTEOMICS This is a preprint and has not been peer reviewed. Data may be preliminary. 17 January 2025 V1 Latest version Share on From Discovery to Implementation: Bringing Proteomics to the Clinic Authors : Agnieszka Latosinska 0000-0001-8917-2412 , Harald Mischak 0000-0003-0323-0306 , and Antonia Vlahou 0000-0003-3284-5713 [email protected] Authors Info & Affiliations https://doi.org/10.22541/au.173711390.00690499/v1 Published PROTEOMICS Version of record Peer review timeline 288 views 249 downloads Contents Abstract Information & Authors Metrics & Citations View Options References Figures Tables Media Share Abstract Implementing proteomics-based solutions has emerged as a potentially highly powerful and transformative approach in enhancing patient management by streamlining clinical decision-making and accelerating drug development. Specific changes in proteins are generally responsible for onset and progression of disease. This understanding serves as a foundation for identifying biomarkers, discovering drug targets, and developing novel therapeutics. Despite substantial progress, several challenges and gaps persist. These include among others technical limitations, regulatory hurdles, legal, ethics and data protection issues. Addressing these obstacles necessitates a multifaceted approach involving critical evaluation, cross-disciplinary collaboration, and the inclusion of diverse stakeholder perspectives. Such a comprehensive strategy appears essential for advancing proteomics from research to implementation, ultimately benefiting patients. To this end, the PROTEOMICS journal is launching a special section dedicated to clinical proteomics. This initiative aims to highlight the critical aspects of (prote)omics-guided biomarker and drug development, address existing challenges, and propose potential solutions for implementation. By fostering collaboration among scientists, clinicians, patients, regulators, insurance companies, pharmaceutical companies, and funding agencies, we hope to spark discussions that pave the way for adopting proteomics-based approaches to improve patient outcomes. From Discovery to Implementation: Bringing Proteomics to the Clinic Agnieszka Latosinska 1 , Harald Mischak 1 and Antonia Vlahou 2 1 Mosaiques Diagnostics GmbH, Hannover, Germany. 2 Center of Systems Biology, Biomedical Research Foundation of the Academy of Athens, Athens, Greece. Correspondence to: Antonia Vlahou, PhD Center of Systems Biology, Biomedical Research Foundation of the Academy of Athens, Athens, Greece [email protected] Implementing proteomics-based solutions has emerged as a potentially highly powerful and transformative approach in enhancing patient management by streamlining clinical decision-making and accelerating drug development [1]. Specific changes in proteins are generally responsible for onset and progression of disease. By investigating proteins, the key drivers of all biological functions and essential components of any living organism, integrating the influence of environmental factors, proteomics enables a deeper understanding of disease pathophysiology. This understanding serves as a foundation for identifying biomarkers, discovering drug targets, and developing novel therapeutics. The evolution of clinical proteomics has been closely linked with advancements in computational tools for data analysis, mass spectrometry, and high-throughput technologies [2]. Concurrently, guidelines and roadmaps have been established to support application in the clinical context, with emphasis on development and validation of biomarkers [3] . [4]. These guidelines address critical aspects, including meaningful context of use, the need to demonstrate added value over or complementarity to clinical standards, impact on patient care, analytical requirements, and ethical, regulatory, and economic considerations. Collectively, these frameworks aim to facilitate the successful translation of proteomics findings into clinical practice, as also graphically depicted in Figure 1 . Despite substantial progress, several challenges and gaps persist [5]. These include among others technical limitations, regulatory hurdles, legal, ethics and data protection issues [6]. Moreover, new challenges continue to emerge as the field advances. Addressing these obstacles necessitates a multifaceted approach involving critical evaluation, cross-disciplinary collaboration, and the inclusion of diverse stakeholder perspectives. Such a comprehensive strategy appears essential for advancing proteomics from research to implementation, ultimately benefiting patients. Given that the primary goal of clinical research, including proteomics, is implementation, studies in this field must propose actionable strategies for translating their findings into patient care. Biomarkers, for example, must provide actionable information that guides specific clinical interventions. To this end, the PROTEOMICS journal is launching a special section dedicated to clinical proteomics. This initiative aims to highlight the critical aspects of (prote)omics-guided biomarker and drug development, address existing challenges, and propose potential solutions for implementation. By fostering collaboration among scientists, clinicians, patients, regulators, insurance companies, pharmaceutical companies, and funding agencies, we hope to spark discussions that pave the way for adopting proteomics-based approaches to improve patient outcomes. Focus areas and case studies The special section aims to provide a comprehensive overview of the status of proteomics-based implementation across various fields, with an initial focus on oncology, nephrology, and cardiovascular diseases. Case studies will illustrate real-world examples either on the path to implementation or upon reaching it, highlighting the challenges and opportunities encountered along the way. These case studies will be contextualized within an “ecosystem for biomarker and drug discovery and development,” incorporating the perspectives of diverse stakeholders, including patients, clinicians, funders, regulators, insurance providers, and the pharmaceutical industry. Key topics to be addressed include: • Biomarker assay development and validation : Emphasis on demonstrated benefit, context-of-use, statistical assessment and reproducibility. • Drug target identification and development : Highlighting innovative methodologies and strategies. • Regulatory requirements : Insights into regulatory frameworks and pathways for approval. • Clinical integration : Strategies for incorporating biomarkers into clinical practice for patient management and clinical trials. • Economic considerations : Analysis of incentives and reimbursement mechanisms to drive adoption. • Ethical and legal frameworks : Addressing compliance with regulations e.g., GDPR, while balancing the push for open science and data sharing to maximize research impact. Frameworks for ensuring data privacy and security and strategies for navigating competing ethical considerations to ensure both compliance and innovation will be covered. • Emerging technologies and future directions : The role of artificial intelligence (AI) in biomarker discovery and patient stratification; Ensuring patient safety and minimizing bias in AI-driven decision-making; Ethical considerations surrounding AI use, including transparency and accountability. Building an implementation roadmap Through these efforts, we aim to delineate the key elements of an implementation roadmap, identifying critical decision points and strategies for overcoming challenges. The roadmap will be designed to bridge the gap between scientific advancements and clinical application, ensuring that proteomics discoveries translate into tangible benefits for patients. This roadmap will also emphasize the importance of cross-disciplinary collaboration, stakeholder engagement, and sustained investment in infrastructure and education. By fostering these initiatives, we hope to catalyze the adoption of proteomics-based approaches in clinical practice, driving advancements in personalized medicine and improving patient outcomes worldwide. Disclosure HM is the co-founder and co-owner of Mosaiques Diagnostics and AL is an employee of Mosaiques Diagnostics. AV has no potential conflicts of interest to disclose. Figure 1. The implementation-centric cycle involves three interconnected stages that drive the translation of scientific discoveries into clinical practice. The first stage, translational/clinical research, focuses on characterizing molecular differences between, for example, patients and appropriate controls. This stage aims to identify key molecular features that can guide the development of novel therapeutics or biomarkers. The second stage involves translating these insights into tangible products, e.g., drugs or diagnostic tests. These products are designed to address unmet clinical needs, offering significant benefits to patients and demonstrating added value over existing standards of care. The final stage, clinical implementation, ensures that the developed products meet regulatory requirements and are cost-effective. This includes obtaining necessary approvals from regulatory agencies, and integrating the products into healthcare systems. The ultimate goal is to deliver these products to patients, improving clinical outcomes and enhancing patient management. Importantly, the research outputs and data generated throughout this cycle can be shared and reused to support other development avenues, fostering innovation and enabling progress in related fields. This process is highly complex, iterative, and resource-intensive. It requires collaboration across multiple disciplines towards overcoming the challenges inherent in each stage to achieve the ultimate goal of improving patient care and advancing medical practice. REFERENCES [1] Gillette, M. A., Jimenez, C. R., and Carr, S. A. Clinical Proteomics: A Promise Becoming Reality. Mol.Cell Proteomics. , 23 (2024): 100688. [2] Birhanu, A. G. Mass spectrometry-based proteomics as an emerging tool in clinical laboratories. Clin.Proteomics. , 20 (2023): 32. [3] Mischak, H., Apweiler, R., Banks, R. E.et al. Clinical proteomics: a need to define the field and to begin to set adequate standards. Proteomics Clin.Appl. , 1 (2007): 148-156. [4] Mischak, H., Allmaier, G., Apweiler, R.et al. Recommendations for biomarker identification and qualification in clinical proteomics. Sci.Transl.Med. , 2 (2010): 46ps42. [5] Mischak, H., Ioannidis, J. P., Argiles, A.et al. Implementation of proteomic biomarkers: making it work. Eur.J Clin Invest , 42 (2012): 1027-1036. [6] Vlahou, A., Hallinan, D., Apweiler, R.et al. Data Sharing Under the General Data Protection Regulation: Time to Harmonize Law and Research Ethics? Hypertension , 77 (2021): 1029-1035. Information & Authors Information Version history V1 Version 1 17 January 2025 Peer review timeline Published PROTEOMICS Version of Record 20 May 2025 Published Copyright This work is licensed under a Non Exclusive No Reuse License. Collection PROTEOMICS Authors Affiliations Agnieszka Latosinska 0000-0001-8917-2412 Mosaiques diagnostics GmbH View all articles by this author Harald Mischak 0000-0003-0323-0306 Medizinische Hochschule Hannover View all articles by this author Antonia Vlahou 0000-0003-3284-5713 [email protected] Foundation for Biomedical Research of the Academy of Athens View all articles by this author Metrics & Citations Metrics Article Usage 288 views 249 downloads .FvxKWukQNSOunydq8rnd { width: 100px; } Citations Download citation Agnieszka Latosinska, Harald Mischak, Antonia Vlahou. From Discovery to Implementation: Bringing Proteomics to the Clinic. Authorea . 17 January 2025. DOI: https://doi.org/10.22541/au.173711390.00690499/v1 If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download. For more information or tips please see 'Downloading to a citation manager' in the Help menu . Format Please select one from the list RIS (ProCite, Reference Manager) EndNote BibTex Medlars RefWorks Direct import Tips for downloading citations document.getElementById('citMgrHelpLink').addEventListener('click', function() { popupHelp(this.href); return false; }); $(".js__slcInclude").on("change", function(e){ if ($(this).val() == 'refworks') $('#direct').prop("checked", false); $('#direct').prop("disabled", ($(this).val() == 'refworks')); }); View Options View options PDF View PDF Figures Tables Media Share Share Share article link Copy Link Copied! Copying failed. Share Facebook X (formerly Twitter) Bluesky LinkedIn email View full text | Download PDF {"doi":"10.22541/au.173711390.00690499/v1","type":"Article"} Now Reading: Share Figures Tables Close figure viewer Back to article Figure title goes here Change zoom level Go to figure location within the article Download figure Toggle share panel Toggle share panel Share Toggle information panel Toggle information panel Go to previous graphic Go to next graphic Go to previous table Go to next table All figures All tables View all material View all material xrefBack.goTo xrefBack.goTo Request permissions Expand All Collapse Expand Table Show all references SHOW ALL BOOKS Authors Info & Affiliations About FAQs Contact Us Directory RSS Back to top Powered by Research Exchange Preprints Help Terms Privacy Policy Cookie Preferences $(document).ready(() => setTimeout(() => { let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" ")); $.get("/resource/lodash?t="+_bnt); },4000)); (function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'a01057ea5a5306fb',t:'MTc3OTY2ODEwMg=='};var a=document.createElement('script');a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();